286408-85-3

Upstream product

• 676-58-4 methylmagnesium chloride 
• 75783-45-8 (3aR,5R,6aS)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]-2,2-dimethyltetrahydro-2H-furo[2,3-d][1,3]dioxol-6-one 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 114861-14-2 1,2-O-isopropylidene-5-O-(t-butyldiphenylsilyl)-α-D-xylofuranose 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 75-16-1 methylmagnesium bromide 
• 532-20-7 D-xylofuranose 

Downstream Products

• 159312-42-2 (3aR,5R,6R,6aR)-6-Benzyloxy-5-benzyloxymethyl-2,2,6-trimethyl-tetrahydro-furo[2,3-d][1,3]dioxole 
• 155190-92-4 2,4-O-dibenzyl-2-C-methyl-D-erythritol 
• 286408-87-5 (2R,3R)-2,4-Bis-benzyloxy-3-hydroxy-2-methyl-butyraldehyde 
• 42933-13-1 2-C-methyl-D-erythritol 

Relevant academic research and scientific papers

PRMT5 INHIBITORS

The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

Synthesis of tritium labelled 2-C-methyl-D-erythritol, a useful substrate for the elucidation of the methylerythritol phosphate pathway for isoprenoid biosynthesis

Free 2,C-methyl-D-erythritol is utilised for isoprenoid biosynthesis by Escherichia coli mutants lacking the two first enzymes of the methylerythritol phosphate pathway, the deoxyxylulose phosphate synthase and isomero-reductase. For feeding experiments, this tetrol was synthesised with an overall 43% yield from readily available 1,2-O-isopropylidene-α-D- xylofuranose, including the possibility of tritium labelling. (C) 2000 Elsevier Science Ltd.